KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Operating Margin (2016 - 2025)

Supernus Pharmaceuticals has reported Operating Margin over the past 15 years, most recently at 1.86% for Q4 2025.

  • Quarterly Operating Margin fell 1415.0% to 1.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.66% through Dec 2025, down 2100.0% year-over-year, with the annual reading at 8.66% for FY2025, 2100.0% down from the prior year.
  • Operating Margin was 1.86% for Q4 2025 at Supernus Pharmaceuticals, up from 31.35% in the prior quarter.
  • Over five years, Operating Margin peaked at 24.14% in Q2 2021 and troughed at 31.35% in Q3 2025.
  • The 5-year median for Operating Margin is 4.56% (2021), against an average of 4.84%.
  • Year-over-year, Operating Margin soared 2638bps in 2024 and then tumbled -5460bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 3.83% in 2021, then skyrocketed by 435bps to 20.52% in 2022, then crashed by -103bps to 0.61% in 2023, then skyrocketed by 2128bps to 12.29% in 2024, then crashed by -115bps to 1.86% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Operating Margin are 1.86% (Q4 2025), 31.35% (Q3 2025), and 7.34% (Q2 2025).